Mogamulizumab for Adult T-Cell Leukemia/Lymphoma Associated With Increased Mortality

Article

Patients with adult T-cell leukemia/lymphoma treated with mogamulizumab prior to undergoing allo-HSCT were at significantly greater risk for graft-vs-host disease–related mortality.

Patients with adult T-cell leukemia/lymphoma (ATLL) treated with the anti-CCR4 monoclonal antibody mogamulizumab prior to undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) were at significantly greater risk for graft-vs-host disease (GVHD)-related mortality, according to the results of a study published in the Journal of Clinical Oncology.

Mogamulizumab was approved as a treatment for ATLL in Japan; however, according to the study, there have been concerns about the drug’s use pretransplantation because of its effects on regulatory T cells (Tregs).

“This study suggests that the use of mogamulizumab before allo-HSCT significantly worsens clinical outcome mainly because of an increased risk of severe/corticosteroid-refractory acute GVHD,” wrote researchers led by Shigeo Fuji, MD, of the National Cancer Center Hospital in Tokyo. “The results strongly support the clinical relevance of Tregs after allo-HSCT in humans, which is consistent with that in animal models. At present, it seems reasonable to pay careful attention to the use of mogamulizumab for patients with ATLL or other diseases who are eligible for allo-HSCT.”

The researchers studied 996 patients aged 70 or younger who underwent allo-HSCT. All patients were diagnosed with ATLL from 2000 to 2013 and received intensive chemotherapy with multiple drugs at first-line therapy. Prior to transplant, 82 patients underwent treatment with mogamulizumab at a median of 45 days from transplant.

At follow-up, patients who took mogamulizumab experienced significantly more grade 3 or 4 GVHD compared with patients who did not receive mogamulizumab (30.9% vs 17.2%; P < .01). In addition, almost three-quarters of patients (73.4%) in the mogamulizumab group required systemic corticosteroids for acute GVHD compared with 59.8% for the no mogamulizumab group (P = .03).

The researchers calculated that pretransplantation mogamulizumab was associated with an 80% increased risk for grade 3 or 4 acute GVHD (relative risk [RR], 1.80) and twice the risk of refractoriness to systemic corticosteroids for acute GVHD (RR, 2.09; P < .01).

The 1-year cumulative incidence of non-relapse mortality was significantly higher in patients who took mogamulizumab; it was 25.1% in the no mogamulizumab group compared with 43.7% in the mogamulizumab group (P < .01). The estimated probability of 1-year overall survival was 49.4% for the no mogamulizumab group compared with 32.3% in the mogamulizumab group (P < .01).

The researchers evaluated the interval of time between mogamulizumab use and transplantation and found that patients with intervals of less than 50 days had a “dismal clinical outcome,” with an estimated 1-year overall survival rate of 20.2% compared with 44.1% in those patients with an interval of 50 days or greater (P < .01).

“The possible mechanism why the interval between mogamulizumab and allo-HSCT is important should be clarified,” the researchers wrote. “When mogamulizumab is administered before allo-HSCT, it depletes host-derived Tregs at first. When allo-HSCT is conducted soon after mogamulizumab is administered, the concentration of mogamulizumab is high enough to deplete donor-derived Tregs as well, which increases the risk of acute GVHD.”

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content